Early Treatment With Fluconazole May Abrogate the Development of IgG Antibodies in Coccidioidomycosis
|
|
- Malcolm Holt
- 5 years ago
- Views:
Transcription
1 MAJOR ARTICLE Early Treatment With Fluconazole May Abrogate the Development of IgG Antibodies in Coccidioidomycosis George R. Thompson III, 1,2 Jennine M. Lunetta, 1 Suzanne M. Johnson, 1 Sandra Taylor, 3 Derek Bays, 1 Stuart H. Cohen, 2 and Demosthenes Pappagianis 1 1 Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, Davis, California; 2 Department of Internal Medicine, Division of Infectious Diseases, University of California, Davis Medical Center, Sacramento, California; and 3 Department of Public Health Sciences, Division of Biostatistics, University of California, Davis, Davis, California Background. We have observed a number of patients who fail to develop coccidioidal complement fixing (CF) antibody (immunoglobulin [IgG]) after the initiation of early antifungal therapy. Although this is the first description of this phenomenon in mycology, a precedent for the abrogation of the immune response has been observed in other conditions, including primary syphilis and primary Lyme disease. Methods. We conducted a retrospective case-control study to determine any patient-specific risk factors associated with this observation. Additionally, in vitro analysis of the coccidioidal CF (IgG) antigen (Cts1) was performed after Coccidioides was grown under escalating fluconazole concentrations. Results. Seventeen patients persistently positive for coccidioidal IgM antibodies without developing an IgG response (cases) were compared with 64 consecutive patients who did develop coccidioidal CF (IgG) antibodies (controls). Early treatment with antifungals (within 2 weeks of symptom onset) was associated with an abrogation of IgG antibody production (P,.001). With immunodiffusion testing, control serum demonstrated a lack of IgG seroreactivity when Coccidioides posadasii grown in the presence of escalating fluconazole doses ( lg/ml) was used as the antigen; however, control serum remained seroreactive for the presence of IgM. The coccidioidal IgG antigen (Cts1) was shown to be diminished when cultures were grown in the presence of fluconazole, lending further in vitro plausibility to our findings. Conclusions. The abrogation of an IgG response in patients treated early in the course of coccidioidal infection may complicate serodiagnosis and epidemiologic studies, and further study to determine the potential clinical implications should be performed. Coccidioidomycosis (also known as San Joaquin fever or Valley Fever) is caused by infection with the dimorphic fungus Coccidioides (Coccidioides immitis and Coccidioides posadasii). In recent years the incidence of infection within endemic areas has increased, and the Received 14 March 2011; accepted 7 June Correspondence: George R. Thompson, MD, Coccidioidomycosis Serology Laboratory, Department of Medical Microbiology and Immunology, Department of Medicine, Division of Infectious Diseases, University of California, Davis, Davis, CA (grthompson@ucdavis.edu). Clinical Infectious Diseases 2011;53(6):e20 e24 Ó The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please journals.permissions@oup.com /2011/ $14.00 DOI: /cid/cir466 Centers for Disease Control and Prevention have mandated reporting of coccidioidomycosis cases within endemic regions in a concerted effort to define the true incidence and prevalence of infection [1, 2]. Diagnosis is established by recovery of Coccidioides spp. from an affected site, histopathologic demonstration of the organism (proven infection), or a compatible clinical picture combined with mycologic or serologic evidence (probable infection) [3]. The high sensitivity, specificity, and noninvasive nature of serologic testing have allowed this method to remain the mainstay of diagnosis. In most cases, signs and symptoms of infection with Coccidioides spp. begin 7 28 days after the inhalation of arthroconidia. The development of an immunoglobulin (IgM) antibody response follows over e20 d CID 2011:53 (15 September) d Thompson et al
2 the next 7 21 days, followed by the development of an IgG response within 2 3 months of exposure [4]. However, one of the authors (D. P.) has observed a number of patients who produced IgM but failed to develop an IgG response when this would be expected. This appeared to be associated with early fluconazole therapy. It was speculated that fluconazole may inhibit the formation of chitinase the antigen reactive with coccidioidal IgG antibody. Similarly, others have reported a lack of antibody production after early treatment in both primary syphilis [5]and primary Lyme disease [6]. Additionally, early therapy to diminish antibody formation forms the basis for antibiotics in the primary prevention of rheumatic fever during streptococcal pharyngitis [7]. The requirement for the continued presence of antigen to develop an IgG response is the likely basis for these findings. METHODS A retrospective case-control study was designed to test whether a higher incidence of early antifungal therapy (receipt of antifungal therapy,14 days after symptom onset) was seen in patients who failed to develop coccidioidal complement fixing (CF) antibodies (IgG) than in patients who either did not receive antifungal therapy or received antifungal therapy $14 days after symptom onset. This study was approved by the Institutional Review Board of the University of California, Davis. Cases were identified by a review of all patients noted to be persistently positive for IgM antibodies (.90 days) from the Coccidioidomycosis Serology Laboratory database between 2003 and Patients were excluded from evaluation if they developed IgG antibody at any time or if insufficient clinical information was available for chart abstraction. For the control cohort, we included consecutive patients with a known diagnosis of coccidioidomycosis who were evaluated between 2009 and 2010 at the University of California, Davis Medical Center. Patients were excluded from either group if they did not meet previously established criteria for the diagnosis of proven or probable coccidioidomycosis [3]. Chart abstraction was performed to identify demographic variables, including age, sex, and ethnicity; date of symptom onset; antifungal agents prescribed; type of coccidioidal infection; and any comorbid conditions that may have accounted for a failure to manifest an appropriate immunologic response. Data analysis was performed using R software (version 2.10). Differences in demographic characteristics were evaluated using Student s t test for continuous variables and Fisher s exact test for categorical variables. Differences were considered statistically significant at P,.05. Spherule-endospore (SE) cultures were prepared as described elsewhere using the C. posadasii strain Silveira [8]. Cultures were grown in the absence of fluconazole (Pfizer) (growth control) and with increasing concentrations of fluconazole, ranging from Table to 128 lg/ml. Culture filtrates were collected at 72 hours. Serologic testing for the presence of antigens reactive with IgM and IgG antibodies by immunodiffusion was performed as described elsewhere, using previously heated antigen to detect IgM antibody reactivity and unheated antigen to detect the antigen (chitinase Cts1) reactive with IgG [4]. Reverse-transcription polymerase chain reaction analysis of Cts1 messenger RNA (mrna) expression was performed as described elsewhere [8], except the following primers were used for chitinase (Cts1) mrna expression: Cts1 forward, 5#-GTGGTC ATAACCCGCAAGAT-3#; Cts1 reverse, 5#-CGGTGAAGCAA- TAGTGAGCA-3#. Chitinase enzyme activity was measured in solution using a colorimetric method with the chromogenic substrate, p-nitrophenyl b-d-n,n#,n##-triacetylchitotriose (Sigma- Aldrich), as described elsewhere [8]. RESULTS Patient Characteristics IgG antibody developed Characteristic No (n 5 17) Yes (n 5 64) P Age, mean 6 SD, years Male sex, no. (%) 9 (53) 49 (76).07 Race or ethnicity.34 Non-Hispanic white 8 38 Non-Hispanic black 3 14 Hispanic 6 10 Other 0 2 Antifungal therapy,.001,14 days after symptoms days after symptom 2 64 Type of coccidioidal infection.12 Primary pulmonary Cavitary pneumonia 1 1 Disseminated disease or 2 2 meningitis Immunologic impairment a. HIV/AIDS 0 0 Prednisone 2 1 Autoimmune disease 1 1 (Psoriasis) Malignancy/chemotherapy 0 0 Diabetes mellitus 2 6 NOTE. Unless otherwise indicated, numbers indicate numbers of patients. HIV, human immunodeficiency virus. a No statistical comparison was conducted owing to small sample sizes. Table 1 shows the characteristics of the 17 patients who were persistently positive for IgM antibodies without developing an IgG response (case patients). Nine male and 8 female patients, ranging in age from 11 to 70 years (mean, 44.1 years), made up the case group. Sixty-four consecutive patients who developed IgG antibodies served as controls. Five patients had proven Abrogation of the Immune Response in Coccidioidomycosis d CID 2011:53 (15 September) d e21
3 Figure 1. Immunodiffusion testing for presence of coccidioidal antibody. Serologic testing using control human serum (CS) known to be reactive to both coccidioidal precipitin ([hspag]) (immunoglobulin [IgM] antigen) (line of identity indicated by white arrows), and coccidioidal complement fixation antigen (CF Ag) (IgG antigen) (line of identity indicated by black arrows). Results demonstrate a reaction of control serum with both control wells (hspag and CF Ag). Control serum also demonstrates seroreactivity in all other wells, including the growth control well (Coccidioides grown in the absence of fluconazole (''No flu'') (A, C) and wells containing Coccidioides posadasii grown in the presence of escalating fluconazole concentrations (from 0.5 to 128 lg/ml). Reaction was confirmed as IgM after dissolution following the addition of dithiothreiotal. disease (meningitis in 2, pulmonary disease in 3), and the remaining 12 (all pulmonary) had probable disease according to criteria established by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [3]; this conclusion was also supported by the improvement of all patients after initiation of antifungal therapy. Early treatment with antifungals (within 2 weeks of symptom onset) was seen in the majority of patients (15 of 17), and concurrent corticosteroid therapy was seen in 2 of 17 (both also received antifungals). The 2 patients who did not receive early antifungal therapy received fluconazole 3 or 4 weeks after symptom onset. Six patients underwent repeated serum testing until precipitin (IgM) antibody was no longer detectable (mean time to resolution of IgM antibody, 470 days; range, days). The duration of follow-up available ranged from 112 to 1998 days (mean, 602 days). Development of IgG antibodies was significantly associated with initiation of antifungal therapy within 14 days of the appearance of symptoms (P,.001). None of the 15 patients who received antifungal therapy within 14 days of symptoms developed IgG antibody (4 of these 15 patients were culture positive). Of the 66 patients who received antifungal therapy (controls and 2 case patients) after 14 days, all but 2 developed the IgG antibody (1 of the controls was culture positive and receiving chronic prednisone therapy). We additionally found no association between development of IgG antibody and patient ethnicity (P 5.343), nor was the development of IgG antibodies associated with the type of coccidioidal infection (P 5.121). However, in almost all cases, the infection was a primary pulmonary infection (75 of 81 patients) with cavitary pneumonia, disseminated disease, or meningitis in the remaining 6 patients. As mentioned elsewhere, it had been speculated that the growth of C. posadasii in the SE phase in the presence of fluconazole might inhibit the production of chitinase (Cts1), the antigen responsible for IgG seropositivity. Figure 1 shows the seroreactivity of control serum known to be positive for both coccidioidal precipitin (IgM) and CF (IgG) antibodies. The serum is shown to be reactive to both previously heated (60 C) coccidioidin (heated spherulin antigen [hspag]), indicating the presence of IgM antibody (the inner line), and unheated antigen, indicating the presence of IgG antibody. A reaction consistent with IgM was also observed against all Coccidioides preparations, including those grown in the absence of fluconazole (controls in Figures 1A and 1C) and those grown under escalating fluconazole concentrations. A reaction consistent with IgG was observed in filtrates of cultures grown in the absence of fluconazole, and questionable reactions were observed in filtrates from very low concentrations of fluconazole. The presence of IgM was confirmed after dissolution of lines of identity with the addition of dithiothreitol. Figure 2 illustrates the reactivity of control serum known to be positive only for CF (IgG) antibodies with culture filtrates. The serum is shown to be reactive only to CF antigen and growth controls. The failure of these lines to dissolve after the addition of dithiothreitol confirms their identity as IgG. Coccidioides SE phase Cts1 mrna expression declined inversely with fluconazole exposure, whereas ribosomal RNA expression remained unchanged in the presence of escalating fluconazole concentrations (Figure 3). These findings suggest that the observed decline in Cts1 mrna is not secondary to organism-wide decrease in protein synthesis or fungal death, but rather that the reduction may be limited to genes such as CTS1. These results are further substantiated by the reduction in endochitinase activity when a Coccidioides SE phase isolate is exposed to increasing fluconazole concentrations (Figure 4). DISCUSSION Infection with Coccidioides spp. is associated with the development of T- and B-cell immune responses [9]. However, in e22 d CID 2011:53 (15 September) d Thompson et al
4 Figure 2. Immunodiffusion testing for presence of coccidioidal antibody. Serologic testing used control human serum (CS) known to be reactive to coccidioidal complement fixation (CF) antigen (CF Ag) (immunoglobulin [Ig] G antigen) (line of identity indicated by arrows). Results demonstrate a reaction of control serum with CF control well (CF Ag) and growth control well (Coccidioides grown in the absence of fluconazole [''No flu'']). Seroreactivity against the other wells was not observed, confirming the absence of coccidioidal CF antigen when cultures were grown in the presence of fluconazole. our review, some patients with coccidioidal infection failed to mount an IgG response when early antifungal therapy was prescribed. Although this phenomenon appears uncommon, it may complicate serodiagnosis and epidemiologic studies examining the incidence and prevalence of this reportable disease. A precedent for the abrogation of an IgG antibody response after early treatment has been described after antimicrobial therapy in primary syphilis and primary Lyme disease [6, 10]. It is thought that the rapid bactericidal effects of antimicrobial therapy reduce the antigenemia to a degree that immunologic recognition is not well established and T and B cells thus do not interact effectively. Antimicrobial therapy may thus preclude the full development of the IgG response but not the IgM antibody response [10], as was observed in our case-control study reported here. The major antigen for coccidioidal IgM appears to be a glycopeptide, and the major antigen for coccidioidal complement fixation IgG is chitinase Cts1 [11]. In the presence of antifungal therapy, the amount of exposed chitinase may be reduced at a critical early stage in the immune response before a sustained B-cell response has developed. Our in vitro investigation has confirmed antigenic differences in filtrates of cultures grown in the presence of fluconazole, as observed by the immunodiffusion results and total Cts1 mrna expression. Similarly, recent work indicates that another triazole, voriconazole, suppresses expression of the chitinase genes CHT1, CHT2, and CHT3 in Candida albicans [12]. It is unlikely that IgG antibodies are protective against the development of coccidioidal infection in view of both relapses and progression of disease despite high complement fixation (IgG) titers. Although in the past the control of coccidioidomycosis was primarily thought to be T-cell dependent, more recent evidence has suggested a role of B cells in protecting against Coccidioides spp. In fact, vaccination against coccidioidomycosis is not fully protective in B-cell deficient mice [13]. A recent observational study found that patients who received antifungals experienced a higher complication rate (including the development of disseminated disease) after withdrawal of antifungal therapy [14]. In line with our data, this observation could be attributed to diminished humoral immunity after antifungal therapy, but the interval between symptoms and receipt of antifungal therapy was not discussed in the other study. Additionally, a lack of randomization in that study limits the ability to draw inferences on the decision to treat or not to treat primary pulmonary coccidioidomycosis. The clinical implications of a failure to develop IgG antibodies thus remain uncertain. Patients treated within 14 days of symptom onset may have been more symptomatic than those who were not. However, in the absence of prospective trials and assignment of symptom scores at the time of initial clinical presentation, this variable cannot be definitively evaluated. In conclusion, we have observed a statistically significant abrogation of the IgG antibody response in some patients with Figure 3. Effect of fluconazole treatment on chitinase, Cts1, messenger RNA expression during in vitro spherule-endospore (SE) phase. Ethidium bromide stained gels of reverse-transcription polymerase chain reaction (RT-PCR) products from reactions to detect Cts1 and rrna (internal control) transcripts in SE phase cells treated with increasing concentrations of fluconazole. Numbers to right of gels indicate size of RT-PCR product. bp, base pair. Abrogation of the Immune Response in Coccidioidomycosis d CID 2011:53 (15 September) d e23
5 Figure 4. Extracellular endochitinase activity in spherule-endospore phase cultures grown in the presence of escalating fluconazole concentrations. p-np, para-nitrophenol. invasive coccidioidomycosis when early antifungal therapy (,14 days after symptom onset) is initiated. Although this phenomenon is uncommon, it may complicate serodiagnosis and the epidemiology regarding this reportable disease. Furthermore, the potential clinical impact of this phenomenon will need to be analyzed in future studies. It remains to be determined whether abrogation of an IgG antibody response reflects a significant lessening of disease burden after early antifungal therapy, or merely a reduction in antibody response, and clinical follow-up of the case patients is needed. Acknowledgments Potential conflicts of interest. G. R. T. has served as a consultant for Basilea and has received research support from Pfizer. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed in the Acknowledgments section. References 1. Vugia DJ, Wheeler C, Cummings KC, Karon A. Increase in coccidioidomycosis: California, MMWR Morb Mortal Wkly Rep 2009; 58: Sunenshine RH, Anderson S, Erhart L, et al. Public health surveillance for coccidioidomycosis in Arizona. Ann N Y Acad Sci 2007; 1111: De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus group. Clin Infect Dis 2008; 46: Pappagianis D. Serologic studies in coccidioidomycosis. Semin Respir Infect 2001; 16: Talwar S, Tutakne MA, Tiwari VD. VDRL titres in early syphilis before and after treatment. Genitourin Med 1992; 68: Dattwyler RJ, Volkman DJ, Luft BJ, Halperin JJ, Thomas J, Golightly MG. Seronegative Lyme disease: dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med 1988; 319: Karthikeyan G, Mayosi BM. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? Circulation 2009; 120: Lunetta JM, Johnson SM, Pappagianis D. Molecular cloning, characterization and expression analysis of two beta-n-acetylhexosaminidase homologs of Coccidioides posadasii. Med Mycol 2010; 48: Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. Clin Microbiol Rev 2004; 17: Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol 1996; 34: Johnson SM, Pappagianis D. The coccidioidal complement fixation and immunodiffusion-complement fixation antigen is a chitinase. Infect Immun 1992; 60: Yukihiro Kaneko. Voriconazole and micafungin induce chitin synthase genes and reduce chitinase genes in Candida biofilms [abstract F-1669]. In: Program and abstracts of the 110th annual American Society for Microbiology Meeting (San Diego). Washington, DC: American Society for Microbiology, Magee DM, Friedberg RL, Woitaske MD, Johnston SA, Cox RA. Role of B cells in vaccine-induced immunity against coccidioidomycosis. Infect Immun 2005; 73: Ampel NM, Giblin A, Mourani JP, Galgiani JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis 2009; 48: e24 d CID 2011:53 (15 September) d Thompson et al
Title: Public Health Reporting and National Notification for Coccidioidomycosis
10-ID-04 Committee: Infectious Diseases Title: Public Health Reporting and National Notification for Coccidioidomycosis I. Statement of the Problem: In 1994, CSTE passed a resolution recommending key federal
More informationPersistence of Immunoglobulin M or Immunoglobulin G Antibody Responses to Borrelia burgdorferi Years after Active Lyme Disease
MAJOR ARTICLE Persistence of Immunoglobulin M or Immunoglobulin G Antibody Responses to Borrelia burgdorferi 10 20 Years after Active Lyme Disease Robert A. Kalish, 1 Gail McHugh, 1 John Granquist, 1 Barry
More informationDRUG INFORMATION ALERT
Paul Davis From: Sent: To: Subject: TSHP Friday, December 20, 2013 4:03 AM paul.davis@tshp.org 12-20-2013 Drug Info Alert - Unseen Danger: Dust-Born Disease DRUG INFORMATION ALERT
More informationCoccidioidomycosis Update for Primary Care
Coccidioidomycosis Update for Primary Care SW Conference on Medicine April 26, 2018 John N Galgiani MD University of Arizona What Is? Caused by soil fungi Coccidioides immitis Coccidioides posadasii Other
More information3/16/16 COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS. Selected References
10 MARCH 2006 Updated 5 June 2008 Updated 11 February 2011 Updated 4 March 2016 Herbert Boro, M.D., F.A.C.P. Selected References 1. Fiese, Marshall J. 1958. Coccidioidomycosis. Charles C. Thomas. 253 pp.
More informationUphill both ways: Fatigue and quality of life in valley fever
Medical Mycology, 2016, 54, 310 317 doi: 10.1093/mmy/myv097 Advance Access Publication Date: 26 November 2015 Original Article Original Article Uphill both ways: Fatigue and quality of life in valley fever
More informationUpdate on Lyme Disease Surveillance in Wisconsin for Providers and Laboratories
Update on Lyme Disease Surveillance in Wisconsin for Providers and Laboratories Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/14 Protecting and promoting the
More informationJohn Galgiani MD or Fariba Donovan MD PhD Banner University Valley Fever Program
John Galgiani MD or Fariba Donovan MD PhD Banner University Valley Fever Program Drs. Galgiani and Donovan Have no conflicts of interest to disclose Caused by soil fungi Coccidioides immitis Coccidioides
More informationSpecificity of Enzyme Immunoassay for Serologic Coccidioidomycosis Diagnosis Compared to Immunodiffusion
Specificity of Enzyme Immunoassay for Serologic Coccidioidomycosis Diagnosis Compared to Immunodiffusion Item Type Thesis Authors Petein, Nathalie Rights Copyright is held by the author. Digital access
More informationCoccidioidomycosis in Patients with Diabetes Mellitus
The American Journal of Medicine (2006) 119, 964-969 CLINICAL RESEARCH STUDY AJM Theme Issue: Infectious Disease Coccidioidomycosis in Patients with Diabetes Mellitus Ana C. Santelli, MD, a Janis E. Blair,
More informationUsing Hospitalization Data To Estimate The Public Health Burden of Coccidioidomycosis in California
Using Hospitalization Data To Estimate The Public Health Burden of Coccidioidomycosis in California V. Flaherman, R. Hector, G. Rutherford University of California, San Francisco Valley Fever Vaccine Project
More informationGuidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification
More informationValue o f Immunodiffusion Tests in the Diagnosis o f Systemic M ycotic Diseases
A n n a l s of C l i n i c a l L a b o r a t o r y S c i e n c e, Vol. 3, N o. 2 Copyright 1 9 7 3, Institute for Clinical Science Value o f Immunodiffusion Tests in the Diagnosis o f Systemic M ycotic
More informationMike Olbinski. Mike Olbinski. Michael Olbinski
Mike Olbinski Mike Olbinski Michael Olbinski Table of Contents List of Figures and Tables... 3 Executive Summary... 4 Introduction... 5 Epidemiology in Arizona... 7 Reporting Sources and Changes in Laboratory
More informationOpen Forum Infectious Diseases Advance Access published February 11, 2016
Open Forum Infectious Diseases Advance Access published February 11, 2016 1 A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis Michael S. Abers 1,2, Musie
More informationISPUB.COM. Coccidioidomycosis In A Cancer Hospital. A Huaringa INTRODUCTION
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 11 Number 2 Coccidioidomycosis In A Cancer Hospital A Huaringa Citation A Huaringa. Coccidioidomycosis In A Cancer Hospital. The Internet Journal
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationManagement of Coccidioidomycosis in Rheumatic Patients on Biologic Response Modifiers
Management of Coccidioidomycosis in Rheumatic Patients on Biologic Response Modifiers Dominick George Sudano, MD Assistant Professor of Medicine Department of Rheumatology University of Arizona Objectives
More informationCoccidioidomycosis, aka Valley Fever
Coccidioidomycosis, aka Valley Fever Presented to the California Partnership for the San Joaquin Valley June 15, 2018 Karen Haught, MD, MPH Public Health Officer Tulare County Public Health Coccidioidomycosis
More informationTreatment of Coccidioidomycosis-associated Eosinophilic Pneumonia with Corticosteroids
Treatment of Coccidioidomycosis-associated Eosinophilic Pneumonia with Corticosteroids Joshua Malo, MD Yuval Raz, MD Linda Snyder, MD Kenneth Knox, MD University of Arizona Medical Center Department of
More informationCoccidioidomycosis in Rheumatologic Patients. Susan E. Hoover, MD
Coccidioidomycosis in Rheumatologic Patients Susan E. Hoover, MD The problem Prevalence of rheumatoid arthritis is 1% Population of Arizona is 6 million At least 150,000 new cocci infections yearly DMARDs
More informationPrecision Health in Valley Fever Does Ancestry Matter? John N Galgiani MD Valley Fever Center for Excellence University of Arizona
Precision Health in Does Ancestry Matter? John N Galgiani MD University of Arizona Coccidioidomycosis Spectrum of Disease 100 Infections 60 No Symptoms 40 Symptoms 37 Recover Life-Long Immunity 100,000-
More informationCalifornia digging. Task 1 Interpret the chest radiograph. L. Hendriks
Case history An18-yr-old male presented at the emergency department with a 4-week history of fever, coughing and dyspnoea. Symptoms presented on a holiday in California (USA) searching the desert for fossils.
More informationCoccidioidal Meningitis in Kings County A Public Health Perspective
Coccidioidal Meningitis in Kings County A Public Health Perspective Michael L Mac Lean, M.D., M.S. Health Officer, Kings County, California December 1, 2011 Introduction It is particularly important to
More informationLyme Disease Surveillance in Wisconsin Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/2014
Lyme Disease Surveillance in Wisconsin Christopher Steward Division of Public Health Wisconsin Department of Health Services 04/10/2014 Protecting and promoting the health and safety of the people of Wisconsin
More informationAspergillus species. The clinical spectrum of pulmonary aspergillosis
Pentalfa 3 maart 2016 The clinical spectrum of pulmonary aspergillosis Pascal Van Bleyenbergh, Pneumologie UZ Leuven Aspergillus species First described in 1729 * >250 species * ubiquitous Inhalation of
More informationCoccidioidomycosis in Infants: A Retrospective Case Series
Coccidioidomycosis in Infants: A Retrospective Case Series Jessica M. Lee, MD, 1,2 * Ana Lia Graciano, MD, 1,3 Lukasz Dabrowski, MD, 1,4 Brenik Kuzmic, PharmD, 5 and Mary Anne Tablizo, MD 1,6 Summary.
More informationThe Public Health Impact of Coccidioidomycosis in Arizona and California
Int. J. Environ. Res. Public Health 2011, 8, 1150-1173; doi:10.3390/ijerph8041150 OPEN ACCESS Article International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph
More informationLU:research Institutional Repository of Lund University
LU:research Institutional Repository of Lund University This is an author produced version of a paper published in European journal of clinical microbiology & infectious diseases: official publication
More informationEpidemiology and Laboratory Diagnosis of Fungal Diseases
Medical Mycology (BIOL 4849) Summer 2007 Dr. Cooper Epidemiology of Mycoses Epidemiology and Laboratory Diagnosis of Fungal Diseases Mycosis (pl., mycoses) - an infection caused by a fungus Two broad categories
More informationProspective Study of Serologic Tests for Lyme Disease
MAJOR ARTICLE Prospective Study of Serologic Tests for Lyme Disease Allen C. Steere, Gail McHugh, Nitin Damle, and Vijay K. Sikand Center for Immunology and Inflammatory Diseases, Division of Rheumatology,
More informationFighting Coccidioidomycosis Prevention: Vaccine Treatment: Nikkomycin Z. Valley Fever Vaccine Project
Fighting Coccidioidomycosis Prevention: Vaccine Treatment: Nikkomycin Z Valley Fever Vaccine Project A brief history Epidemic of early 90 s spawned renewed interest in a vaccine Bakersfield locals created
More informationThe Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis
REVIEW ARTICLE The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis Elizabeth E. Wack, 1 Neil M. Ampel, 2,3 Rebecca H. Sunenshine, 4,5 and John N. Galgiani 1,2 1 Valley Fever
More informationSTATEMENT FOR MANAGING LYME DISEASE IN NOVA SCOTIA
INFECTIOUS DISEASES EXPERT GROUP (IDEG) DEPARTMENT OF HEALTH AND WELLNESS STATEMENT FOR MANAGING LYME DISEASE IN NOVA SCOTIA Executive Summary: In 2016, the Public Health Agency of Canada (PHAC) modified
More informationIncidence rate per 100,000 persons Year FIGURE 1. The incidence of coccidioidal infection in
Coccidioidomycosis CONCISE REVIEW FOR COCCIDIOIDAL CLINICIANS INFECTION JAMES M. PARISH, MD, AND JANIS E. BLAIR, MD On completion of this article, you should be able to (1) describe the geographic areas
More informationFungal Diseases of the Respiratory System
Fungal Diseases of the Respiratory System Histoplasmosis(cave disease) Dr. Hala Al Daghistani Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. Histoplasma capsulatum, is usually
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationLyme Disease. Abstract Lyme disease is a vector borne infection primarily transmitted by Ixodes ticks and. Special Issue
Special Issue Lyme Disease Min Geol Lee, M.DYoung Hun Cho, M.D. Department of Dermatology Yonsei University College of Medicine, Severance Hospital Email : mglee@yumc.yonsei.ac.krsalute@yumc.yonsei.ac.kr
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More information2046: Fungal Infection Pre-Infusion Data
2046: Fungal Infection Pre-Infusion Data Fungal infections are significant opportunistic infections affecting transplant patients. Because these infections are quite serious, it is important to collect
More informationInfectious Diseases Expert Group (IDEG) Department of Health and Wellness. Statement for Managing Lyme Disease in Nova Scotia
Infectious Diseases Expert Group (IDEG) Department of Health and Wellness Statement for Managing Lyme Disease in Nova Scotia 2018 Executive Summary: In 2016, the Public Health Agency of Canada (PHAC) modified
More informationLyme Neuroborreliosis
Lyme Neuroborreliosis Presenter: Elitza S. Theel, Ph.D., D(ABMM) Director of Infectious Diseases Serology Co-Director, Vector-Borne Diseases Service Line Department of Laboratory Medicine and Pathology
More informationCalifornia Association for Medical Laboratory Technology
California Association for Medical Laboratory Technology Distance Learning Program COCCIDIOIDOMYCOSIS (VALLEY FEVER): A REEMERGING MYCOSIS Course # DL-993 by Lucy Treagan, Ph.D. Prof. Biology, Emerita
More information3. Rapidly recognize influenza seasons in which the impact of influenza appears to be unusually severe among children.
07-ID-14 Committee: Title: Infectious Disease Influenza-Associated Pediatric Mortality Statement of the Problem: In 2004, CSTE adopted influenza-associated pediatric mortality reporting with a provision
More informationLYME DISEASE Last revised May 30, 2012
Wisconsin Department of Health Services Division of Public Health Communicable Disease Surveillance Guideline LYME DISEASE Last revised May 30, 2012 I. IDENTIFICATION A. CLINICAL DESCRIPTION: A multi-systemic
More informationEpidemiologic, Clinical, and Diagnostic Aspects of Coccidioidomycosis
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 26 30 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.02230-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Epidemiologic,
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Influenza Revised December 2014 Influenza 1.0 Provincial Reporting Confirmed cases of disease 2.0 Type
More informationTitle Coccidioidomycosis (Valley fever) case data for the southwestern United States
Open Health Data: 1. Overview Title Coccidioidomycosis (Valley fever) case data for the southwestern United States Paper Authors 1. Gorris, Morgan E.; (Lead/corresponding author) 2. Cat, Linh A.; 3. Matlock,
More information2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
Clinical Infectious Clinical Diseases Infectious Diseases Advance Access published July 27, 2016 IDSA GUIDELINE 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationDisseminated Coccidioidomycosis of the Rearfoot: A case report
Open Access Publication Disseminated Coccidioidomycosis of the Rearfoot: A case report by Robert Frykberg, DPM, MPH 1 4 Tierney, DPM 2 3, Beth Noe, DPM, Stephanie Michael, DPM, Edward The Foot & Ankle
More informationEVALUATION OF LYME DISEASE TESTS. I would like to thank Dr. Dumler for his reply to my letter expressing concerns regarding
Note: Andrew Onderdonk, editor of The Journal of Clinical Microbiology has refused to ask Dumler to dislose the results of his study or explain his erroneous arithmetic. Dumler has not provided results
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationCOCCIDIOIDES SPP. EXPOSURE/INJURY RESPONSE PROTOCOL
PLEASE POST THIS PAGE IN AREAS WHERE COCCIDIOIDES IS USED IN RESEARCH LABORATORIES UNIVERSITY OF CALIFORNIA, SAN FRANCISCO ENVIRONMENTAL HEALTH AND SAFETY/BIOSAFETY COCCIDIOIDES SPP. EXPOSURE/INJURY RESPONSE
More informationCoccidioidomycosis: DISCLOSURES. Key Questions. Coccidioides: Life Cycle. Epidemiology. Origin of Coccidioides spp? 3/25/2018
Coccidioidomycosis: Recent Advances and Remaining Problems DISCLOSURES Name of Organization Relationship George R. Thompson III, MD, FIDSA Associate Professor Division of Infectious Diseases Department
More informationCoccidioidomycosis as a Cause of Sarcoid in Arizona
Coccidioidomycosis as a Cause of Sarcoid in Arizona Item Type Thesis Authors Yourison, Isaac Publisher The University of Arizona. Rights Copyright is held by the author. Digital access to this material
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationOutline. Cryptococcosis Pneumocystosis Diarrhea. Case Histories: HIV Related- Opportunistic Infections in 2015
AU Edited: 05/06/15 Case Histories: HIV Related- Opportunistic Infections in 2015 Henry Masur, MD Clinical Professor of Medicine George Washington University School of Medicine Bethesda, Maryland Washington,
More informationResearch priorities in medical mycology
Research priorities in medical mycology David W. Denning National Aspergillosis Centre University Hospital of South Manchester The University of Manchester Agenda How many patients are there with serious
More informationRoyce Johnson, M.D., F.A.C.P. Disclosure Information Research Support/Consultant/Speaker
Royce Johnson, M.D., F.A.C.P. Disclosure Information Research Support/Consultant/Speaker Astellas Enzon Pharmaceuticals Merck & Co, Inc. Ortho-McNeil, Inc. Pfizer, Inc. Sanofi Aventis Schering-Plough The
More informationEpidemiology of Fungal Diseases
Lecture 2 Epidemiology of Fungal Diseases Disclaimer: This lecture slide presentation is intended solely for educational purposes. Many of the images contained herein are the property of the original owner,
More informationThe goal of teaching:
The goal of teaching: 1. Principles of LDG of SFI: Hair Nail Skin Mucosal Eye Ear 3. Methods for fungal identification Test methods for fungal susceptibility testing Diffusion Dilution Etest 2. Principles
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationUpdate from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance 13
Fungal Infections Preface: Fungal Infections Luis Ostrosky-Zeichner and Jack D. Sobel xiii The Global Burden of Fungal Diseases 1 Snigdha Vallabhaneni, Rajal K. Mody, Tiffany Walker, and Tom Chiller Fungal
More informationViral Genetics. BIT 220 Chapter 16
Viral Genetics BIT 220 Chapter 16 Details of the Virus Classified According to a. DNA or RNA b. Enveloped or Non-Enveloped c. Single-stranded or double-stranded Viruses contain only a few genes Reverse
More informationExplanation of the Lyme Disease Western Blot
1 of 5 09/05/2008 16:30 From: BCLyme Newsgroups: sci.med.diseases.lyme Subject: Helpful info for understanding the LD Western blot test NNTP-Posting-Host: ladder05.news.aol.com X-Admin: news@aol.com Date:
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Antibiotic Therapy for Lyme Disease File Name: intravenous_antibiotic_therapy_for_lyme_disease Origination: 3/2006 Last CAP Review: 2/2017 Next CAP Review: 2/2018 Last
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationSELECTED INFECTIONS ACQUIRED DURING TRAVELLING IN NORTH AMERICA. Lin Li, MD August, 2012
SELECTED INFECTIONS ACQUIRED DURING TRAVELLING IN NORTH AMERICA Lin Li, MD August, 2012 Case 1 32 year old male working in Arizona; on leave back in Singapore Presented to hospital A for fever x (7-10)
More informationCoccidioidomycosis, also called, is caused
REVIEW Coccidioidomycosis in African Americans Barbara E. Ruddy, MD; Anita P. Mayer, MD; Marcia G. Ko, MD; Helene R. Labonte, DO; Jill A. Borovansky, MD; Erika S. Boroff, MD; and Janis E. Blair, MD Coccidioidomycosis
More informationParacoccidiomycosis and HIV/AIDS: A Common Problem in an Uncommon Location
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Paracoccidiomycosis and HIV/AIDS: A Common Problem in an Uncommon Location Astrid Radermacher DO Lehigh Valley Health Network, Astrid.Radermacher@lvhn.org
More informationAlberta Health and Wellness Public Health Disease Under Surveillance Management Guidelines March 2011
March 2011 Histoplasmosis Case Definition Confirmed Case Clinical illness [1] with laboratory confirmation of infection: Isolation of Histoplasma capsulatum from an appropriate clinical specimen (tissue
More informationMAJOR ARTICLE. John A. Branda, 1 Katy Linskey, 1 Yeowon A. Kim, 1 Allen C. Steere, 2 and Mary Jane Ferraro 1,2
MAJOR ARTICLE Two-Tiered Antibody Testing for Lyme Disease With Use of 2 Enzyme Immunoassays, a Whole-Cell Sonicate Enzyme Immunoassay Followed by a VlsE C6 Peptide Enzyme Immunoassay John A. Branda, 1
More informationCoping with Valley Fever Information for Families
Coping with Valley Fever Information for Families Valley Children s Healthcare & University of California, Merced 9300 Valley Children s Place Madera, CA 93636 Social Worker: Margie Arreguin-Zarate, LCSW
More informationOverview of Coccidioidomycosis (Valley Fever) Stephen Munday, MD MPH Imperial County Public Health May 21, 2013
Overview of Coccidioidomycosis (Valley Fever) Stephen Munday, MD MPH Imperial County Public Health May 21, 2013 Objectives Assess the epidemiology of Coccidioidomycosis (aka Valley Fever) Describe the
More informationPeter J. Weina, PhD, MD, FACP, FIDSA. Colonel, Medical Corps, US Army Deputy Commander Walter Reed Army Institute of Research
Peter J. Weina, PhD, MD, FACP, FIDSA Colonel, Medical Corps, US Army Deputy Commander Walter Reed Army Institute of Research Background Most common vector-borne disease in U.S. First described in Lyme,
More informationFungal (Aspergillus and Candida) infections in Cystic fibrosis
Fungal (Aspergillus and Candida) infections in Cystic fibrosis Malena Cohen-Cymberknoh, MD CF Center Hadassah-Hebrew University Medical Center Jerusalem, Israel Israeli Annual CF Conference, Herzlyia,
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationA bs tr ac t. n engl j med 367;20 nejm.org november 15,
The new england journal of medicine established in 1812 november 15, 2012 vol. 367 no. 20 Differentiation of Reinfection from Relapse in Recurrent Lyme Disease Robert B. Nadelman, M.D., Klára Hanincová,
More information10/19/2012. Serologic Testing for Syphilis. Disclosures. Comparison of the Traditional and Reverse Screening Algorithms. Outline.
Serologic Testing for Syphilis Comparison of the Traditional and Reverse Screening Algorithms Disclosures Elli S. Theel, Ph.D. Director, Infectious Diseases Serology Laboratory Assistant Professor of Laboratory
More information3. Lymphocyte proliferation (fig. 15.4): Clones of responder cells and memory cells are derived from B cells and T cells.
Chapter 15 Adaptive, Specific Immunity and Immunization* *Lecture notes are to be used as a study guide only and do not represent the comprehensive information you will need to know for the exams. Specific
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Feder HM Jr, Johnson BJB, O Connell S, et al. A critical appraisal
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationPractice Guidelines for the Management of Patients with Blastomycosis
679 Practice Guidelines for the Management of Patients with Blastomycosis Stanley W. Chapman, 1 Robert W. Bradsher, Jr., 2 G. Douglas Campbell, Jr., 3 Peter G. Pappas, 4 and Carol A. Kauffman 5 From the
More informationTwo-Year Evaluation of Borrelia burgdorferi Culture and Supplemental Tests for Definitive Diagnosis of Lyme Disease
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2005, p. 5080 5084 Vol. 43, No. 10 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.10.5080 5084.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationCase Report Coccidioides immitis Cervical Lymphadenitis Complicated by Esophageal Fistula
Case Reports in Infectious Diseases Volume 2016, Article ID 8715405, 4 pages http://dx.doi.org/10.1155/2016/8715405 Case Report Coccidioides immitis Cervical Lymphadenitis Complicated by Esophageal Fistula
More informationSerodiagnosis in Early Lyme Disease
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1993, p. 3090-3095 Vol. 31, No. 12 0095-1137/93/123090-06$02.00/0 Copyright 0) 1993, American Society for Microbiology Serodiagnosis in Early Lyme Disease MARIA E.
More informationCurrent Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections
CLINICAL MICROBIOLOGY REVIEWS, July 2002, p. 465 484 Vol. 15, No. 3 0893-8512/02/$04.00 0 DOI: 10.1128/CMR.15.3.465 484.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Current
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationSerological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections?
Abstract no. WEPE 494 Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections? G.Chrysos 1, D.Karageorgopoulos
More informationIntroduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationChapter 1. Full file at
Chapter 1 1. Which is the best definition of immunity? Answer: B A. The state of having been exposed to a pathogen repeatedly B. The state of being resistant to reinfection with a pathogen C. When an individual
More informationLecture 7: Mycoses Caused by Dimorphic Fungi, Part I
BIOL 4849 Medical Mycology Summer 2006 Histoplasmosis Lecture 7: Mycoses Caused by Dimorphic Fungi, Part I u Most common endemic mycotic disease in the United States u Two different varieties (actually
More informationTreatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series
MAJOR ARTICLE Treatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series Emily R. Levy, 1 James M. McCarty, 2,3 Andi L. Shane, 4 and
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More information